<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980603</url>
  </required_header>
  <id_info>
    <org_study_id>NCCCTS-07-296</org_study_id>
    <nct_id>NCT00980603</nct_id>
  </id_info>
  <brief_title>Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer</brief_title>
  <official_title>A Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-line Chemotherapy After Cisplatin Plus S-1 or Capecitabine in Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of docetaxel alone, docetaxel plus&#xD;
      cisplatin, and docetaxel plus S-1 in patients with metastatic gastric cancer after failing&#xD;
      1st line chemotherapy with cisplatin plus S-1 or capecitabine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, the most commonly used first-line chemotherapies have been based on fluorouracil&#xD;
      and/or cisplatin in patients with metastatic gastric cancer. Unfortunately, considerable&#xD;
      proportions of patients with metastatic gastric cancer do not respond to first-line&#xD;
      chemotherapy and most of the patients who do respond eventually experience disease&#xD;
      progression. In the second-line treatment, however, standard therapies are less clearly&#xD;
      defined.&#xD;
&#xD;
      Meanwhile, regarding re-challenge of previous failed drugs as a combination with an other&#xD;
      newly introduced chemotherapeutic agent, there are few data. Increased expression and&#xD;
      activity of thymidylate synthase, which is inhibited by fluoropyrimidine, is regarded to be&#xD;
      the main reason for the development of clinical resistance to fluoropyrimidine. Since the&#xD;
      cotreatment of docetaxel and 5-fluorouracil decreases the activity and expression of&#xD;
      thymidylate synthase and dihydropyrimidine dehydrogenase (5-fluorouracil degradation enzyme),&#xD;
      and increases the expression of orotate phosphoribosyl transferase, the addition of docetaxel&#xD;
      into S-1 may recover the sensitivity to S-1 in patients previously resistant to S-1.&#xD;
&#xD;
      Several reports found that MDR-1 and MRP-1 are related to cisplatin-resistance; cisplatin&#xD;
      induces the overexpression of MRP-1, which reduces intracellular cisplatin accumulation.&#xD;
      Since docetaxel suppresses the cisplatin-induced MRP-1 upregulation, the addition of&#xD;
      docetaxel into cisplatin may recover the sensitivity to cisplatin in patients previously&#xD;
      resistant to cisplatin.&#xD;
&#xD;
      Based on these synergism mechanisms, we speculate that the cotreatment of docetaxel and&#xD;
      cisplatin or S-1 has better anti-tumor activity than docetaxel alone in patients resistant to&#xD;
      cisplatin or S-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>every 2 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>doctaxel plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>docetaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, cisplatin</intervention_name>
    <description>docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>doctaxel plus cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, S-1</intervention_name>
    <description>docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops</description>
    <arm_group_label>docetaxel plus S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed gastric adenocarcinoma with metastatic&#xD;
             disease&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-2&#xD;
&#xD;
          -  At least one measurable lesion as defined by RECIST&#xD;
&#xD;
          -  Only one prior chemotherapy containing both S-1 or capecitabine and cisplatin for&#xD;
             metastatic gastric cancer with documented progression of disease occurring during&#xD;
             chemotherapy or within 6 months of completion of chemotherapy&#xD;
&#xD;
          -  Adequate major organ function:&#xD;
&#xD;
        ANC ≥1,500/mm3, Platelet ≥100,000/mm3, serum bilirubin ≤1.5 x upper limit of normal (ULN),&#xD;
        AST/ALT ≤2.5 x ULN (≤5 x ULN if liver metastases are present), creatinine clearance ≥50&#xD;
        ml/min using the calculation formula or 24 hours urine collection&#xD;
&#xD;
          -  Patients should sign a written informed consent before study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior taxane treatment&#xD;
&#xD;
          -  Major surgery or radiotherapy less than 4 weeks prior to entry&#xD;
&#xD;
          -  NCI CTCAE (version 3.0) adverse events ≥grade 2 except alopecia, fatigue, and weight&#xD;
             loss&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome, or inability to take oral medication&#xD;
&#xD;
          -  Patients with active gastrointestinal bleeding&#xD;
&#xD;
          -  Inadequate cardiovascular function&#xD;
&#xD;
          -  Serious concurrent infection or nonmalignant illness that is uncontrolled or whose&#xD;
             control may be jeopardized by complications of study therapy&#xD;
&#xD;
          -  Other malignancy within the past 3 years except adequately treated non-melanomatous&#xD;
             skin cancer, carcinoma in situ of the cervix, or in situ of prostate cancer Gleason≤7&#xD;
&#xD;
          -  Psychiatric disorder that would preclude compliance&#xD;
&#xD;
          -  Patients receiving a concomitant treatment with drugs interacting with S-1 such as&#xD;
             flucytosine, phenytoin, or allopurinol&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding or adults of reproductive potential&#xD;
             not employing effective method of birth control&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sook Ryun Park, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute and Hospital, National Cancer Center Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sook Ryun Park, Dr.</last_name>
    <phone>82-31-920-1609</phone>
    <phone_ext>1609</phone_ext>
    <email>sukryun73@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Lan Park, CRC</last_name>
    <phone>82-31-920-0422</phone>
    <phone_ext>0422</phone_ext>
    <email>lan0729@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Chonju</city>
        <zip>361-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye-Suk Han, M.D.</last_name>
      <email>sook3529@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hye-Suk Han, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute and Hospital, National Cancer Center Korea</name>
      <address>
        <city>Goyang</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sook Ryun Park, M.D.</last_name>
      <phone>82-31-920-1609</phone>
      <phone_ext>1609</phone_ext>
      <email>sukryun73@hanmail.net</email>
    </contact>
    <contact_backup>
      <last_name>Young Lan Park, RN</last_name>
      <phone>82-31-920-0422</phone>
      <phone_ext>0422</phone_ext>
      <email>lan0729@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Sook Ryun Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noe Kyeong Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngiee Park, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Byung-Ho Nam, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Inchon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Bok Shin, M.D., Ph.D.</last_name>
      <email>dbs@gilhospital.com</email>
    </contact>
    <investigator>
      <last_name>Dong Bok Shin, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sun Jin Sym, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keun-Wook Lee, M.D., Ph.D.</last_name>
      <email>hmodoctor@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Keun-Wook Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <last_update_submitted>September 18, 2009</last_update_submitted>
  <last_update_submitted_qc>September 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sook Ryun Park/Dr.</name_title>
    <organization>Research Institute and Hospital, National Cancer Center</organization>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>docetaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>S-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

